Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications - Archive ouverte HAL
Article Dans Une Revue Blood Advances Année : 2024

Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications

Eric Letouzé
Philippe Moreau
  • Fonction : Auteur
Nikhil Munshi
  • Fonction : Auteur
Mehmet Samur
  • Fonction : Auteur
Cyrille Touzeau
  • Fonction : Auteur

Résumé

Abstract Bispecific T-cell engagers (TCEs) are revolutionizing patient care in multiple myeloma (MM). These monoclonal antibodies, that redirect T cells against cancer cells, are now approved for the treatment of triple-class exposed relapsed/refractory MM (RRMM). They are currently tested in earlier lines of the disease, including in first line. Yet, primary resistance occurs in about one-third of patients with RRMM, and most responders eventually develop acquired resistance. Understanding the mechanisms of resistance to bispecific TCE is thus essential to improve immunotherapies in MM. Here, we review recent studies investigating the clinical and molecular determinants of resistance to bispecific TCE. Resistance can arise from tumor-intrinsic or tumor-extrinsic mechanisms. Tumor-intrinsic resistance involves various alterations leading to the loss of the target antigen, such as chromosome deletions, point mutations, or epigenetic silencing. Loss of major histocompatibility complex (MHC) class I, preventing MHC class I: T-cell receptor (TCR) costimulatory signaling, was also reported. Tumor-extrinsic resistance involves abundant exhausted T-cell clones and several factors generating an immunosuppressive microenvironment. Importantly, some resistance mechanisms impair response to 1 TCE while preserving the efficacy of others. We next discuss the clinical implications of these findings. Monitoring the status of target antigens in tumor cells and their immune environment will be key to select the most appropriate TCE for each patient and to design combination and sequencing strategies for immunotherapy in MM.
Fichier principal
Vignette du fichier
Letouzé et al blooda_adv-2023-012354-main.pdf (1.03 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04658355 , version 1 (29-07-2024)

Identifiants

Citer

Eric Letouzé, Philippe Moreau, Nikhil Munshi, Mehmet Samur, Stéphane Minvielle, et al.. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Advances, 2024, 8 (11), pp.2952-2959. ⟨10.1182/bloodadvances.2023012354⟩. ⟨hal-04658355⟩
31 Consultations
9 Téléchargements

Altmetric

Partager

More